Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (2204)	3/31/1999 2:07:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

Late New, Gruntal upgrades RESEARCH ALERT - Sepracor a strong buy Wednesday, March 31, 1999 01:21 PM Mail this article to a friend new! LOS ANGELES, March 31 (Reuters) - Gruntal & Co raised its rating on shares of drug company Sepracor Inc to strong buy from buy after what Gruntal called "a very bullish" speech by Chief Financial Officer David Southwell to a group of institutional investors. -- said given company's $40 billion target for new drugs, technology validation and earnings projection of $12.10 per share in 2003, stock could rise to $155 a share in next year. -- said stock at $111 a share, down from a recent high of $141, presents a buying opportunity. -- Sepracor shares were up 1-3/8 at 111-7/8 by midday. Quote for referenced ticker symbols: SEPR © 1999, Reuters